Target Validation in Drug Discovery
Published on 1. November 2006
Book
Hardback
296 pages
978-0-12-369393-8 (ISBN)
Description
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
More details
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.
Dimensions
Height: 260 mm
Width: 184 mm
Weight
820 gr
ISBN-13
978-0-12-369393-8 (9780123693938)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Brian W. Metcalf | Susan Dillon
Target Validation in Drug Discovery
E-Book
04/2011
Academic Press
€83.95
Available for download
Persons
Content
I: Pharmaceutical biotechnology for target validation
Chapter 1: GENERATION OF TRANSGENIC ANIMALS
Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS
II: Target validation for biopharmaceutical drug discovery
Chapter 3: CETUXIMAB (ERBITUX (R)), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE
Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES
Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE
Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
III: Validating targets of small molecule approaches
Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS
Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION
Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS
Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST
Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY
INDEX
Chapter 1: GENERATION OF TRANSGENIC ANIMALS
Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS
II: Target validation for biopharmaceutical drug discovery
Chapter 3: CETUXIMAB (ERBITUX (R)), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE
Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES
Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE
Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
III: Validating targets of small molecule approaches
Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS
Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION
Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS
Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST
Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY
INDEX